ArticleOncotarget2018
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.
Luc Cabel et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
10 papers cite it
this paperpooled itcites it
ArticleOncotarget2018
Luc Cabel et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.